843 related articles for article (PubMed ID: 29225305)
21. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
Tomita T
Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
[TBL] [Abstract][Full Text] [Related]
22. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
Conway KA; Baxter EW; Felsenstein KM; Reitz AB
Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
[TBL] [Abstract][Full Text] [Related]
23. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
Ling S; Zhou J; Rudd JA; Hu Z; Fang M
Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
[TBL] [Abstract][Full Text] [Related]
24. The FAM3 superfamily member ILEI ameliorates Alzheimer's disease-like pathology by destabilizing the penultimate amyloid-β precursor.
Hasegawa H; Liu L; Tooyama I; Murayama S; Nishimura M
Nat Commun; 2014 Jun; 5():3917. PubMed ID: 24894631
[TBL] [Abstract][Full Text] [Related]
25. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
[TBL] [Abstract][Full Text] [Related]
26. The Y
Matrone C; Iannuzzi F; Annunziato L
Ageing Res Rev; 2019 Jul; 52():120-128. PubMed ID: 31039414
[TBL] [Abstract][Full Text] [Related]
27. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies.
Christensen DD
CNS Spectr; 2007 Feb; 12(2):113-6, 119-23. PubMed ID: 17277711
[TBL] [Abstract][Full Text] [Related]
29. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
30. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
Ising C; Stanley M; Holtzman DM
Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
[TBL] [Abstract][Full Text] [Related]
31. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
Barage SH; Sonawane KD
Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
[TBL] [Abstract][Full Text] [Related]
32. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
33. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.
Panza F; Frisardi V; Imbimbo BP; Capurso C; Logroscino G; Sancarlo D; Seripa D; Vendemiale G; Pilotto A; Solfrizzi V
CNS Neurosci Ther; 2010 Oct; 16(5):272-84. PubMed ID: 20560993
[TBL] [Abstract][Full Text] [Related]
34. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
35. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
Boutajangout A; Wisniewski T
Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
[TBL] [Abstract][Full Text] [Related]
36. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
37. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
[TBL] [Abstract][Full Text] [Related]
38. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
39. [Production and catabolism of amyloid peptides in Alzheimer's disease].
Checler F
Therapie; 2010; 65(5):409-14. PubMed ID: 21144475
[TBL] [Abstract][Full Text] [Related]
40. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
